Financings

Anergis SA pulled in CHF18 million (US$19.6 million in Series A funding.

Arena Pharmaceuticals Inc. priced a $35.5 million offering of common and preferred stock.

AssureRx Health Inc. raised $11 million in a Series B round.

Insys Therapeutics Inc. filed for a $55 million IPO.

Rexahn Pharmaceuticals Inc. added $10 million via a registered direct offering.

Spectrum Pharmaceuticals Inc. received clearance for a data monitoring committee to continue the pivotal trial of belinostat in relapsed or refractory peripheral T-cell lymphoma.

Deals

Alnylam Pharmaceuticals Inc. picked up a $10 million tech transfer payment from Takeda Pharmaceutical Co. Ltd.

Apthera Inc. agreed to merge with RXi Pharmaceuticals Corp. in a stock deal.

Cephalon Inc. agreed to buy ChemGenex Pharmaceuticals Ltd. for $231 million.

Intercept Pharmaceuticals Inc. inked a potential $315 million Asian deal for FXR agonist obeticholic acid with Dainippon Sumitomo Pharma Co. Ltd.

Valeant Pharmaceuticals International Inc. made a $5.7 billion hostile bid for Cephalon Inc.

. . . And More

Amgen Inc. and partner Takeda Pharmaceutical Co. Ltd. disclosed disappointing top-line results from a Phase III trial of motesanib in lung cancer.

Biogen Idec Inc. and Knopp Biosciences Inc. enrolled the first patient in a Phase III trial of ALS drug dexpramipexole.

Bristol-Myers Squibb Co. wins a better-than-expected label for melanoma drug Yervoy (ipilimumab).

Myrexis Inc. said it is trimming its work force by 57 employees, or 41 percent, primarily in internal drug discovery.

Onyx Pharmaceuticals Inc. expanded its Phase III European trial of next-generation proteasome inhibitor carfilzomib in relapsed and refractory myeloma to look at overall survival as the primary endpoint.

Polaris Group's ADI-PEG 20 candidate for hepatocellular carcinoma got a special protocol assessment for a Phase III study.

Vertex Pharmaceuticals Inc. reported positive data from its pediatric trial of cystic fibrosis candidate VX-770.